SAN DIEGO, Sept. 1, 2016 /PRNewswire/ -- OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in September, including: Rodman & Renshaw 18th Annual Global Investment Conference and Bioelectrics 2016: 13th International Bioelectrics Symposium.
Rodman & Renshaw 18th Annual Global Investment Conference
Punit Dhillon will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference on September 12 at 10:00 AM ET at The Lotte New York Palace Hotel in New York City. To view to the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/rrshq26/oncs/. An archived version of the webcast will be available for 90 days on OncoSec’s website: http://www.oncosec.com.
This conference brings together growth companies and a vast audience of financial and strategic investors for in-depth corporate presentations as well as to facilitate one-on-one investor and networking meetings. The conference will focus on tracks dedicated to healthcare; natural resources; technology, media and telecommunications; clean tech. For more information, please visit: http://www.rodm.com.
Bioelectrics 2016: 13th International Bioelectrics Symposium
Richard Connolly, PhD, Director of Bioengineering at OncoSec, will present an invited lecture entitled: “Adaptive Electroporation Technology for Intratumoral Immunotherapy” at the 13th International Bioelectrics Symposium on September 12 at 9:45 AM CEST at the Penta Hotel in Rostock, Germany.
The symposium presents a forum to discuss research and applications regarding the interactions of electrical stimuli with living cells, in particular pulsed electric fields and non-thermal plasmas. Research topics and applications covered during the symposium include: biological responses; biophysics and biochemistry of interaction mechanisms; exposure devices and methods, and cancer treatment and tumor ablation. For more information, please visit: http://www.bioelectrics2016.org/.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response. ImmunoPulse® IL-12, OncoSec’s lead program, is currently in clinical development for several indications, including metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.
CONTACT:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-in-september-300321124.html
SOURCE OncoSec Medical Incorporated
